Telix to Acquire Therapeutic Assets & Biologics Platform from ImaginAb for ~$230M
Shots:
- Telix to acquire next-gen. therapeutic pipeline, biologics tech platform as well as research facility focused on protein engineering & discovery from ImaginAb via an asset purchase agreement to bolster its capabilities
- As per the terms, Telix will acquire candidates incl. DLL3 & integrin αvβ6 antagonist, plus a tech platform utilizing small engineered Ab format & a facility in California in exchange for $45M ($10M cash + $31M equity + ~$4M deferred equity payout after 15mos.)
- In addition, ImaginAb will also receive $185M as milestones in cash/equity, net-sales-based low single-digit royalties on limited platform & early-stage products after the development of 4 programs, plus single-digit sublicense fees
Ref: Telix Pharmaceuticals | Image: Telix Pharmaceuticals & ImaginAb
Related News:- Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
